Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Volume 68, Number 22, May 29, 2007
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tan, Z. S.
Right arrow Articles by Seshadri, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tan, Z. S.
Right arrow Articles by Seshadri, S.
Related Collections
Right arrow Autoimmune diseases
Right arrow All Cognitive Disorders/Dementia
Right arrow Alzheimer's disease
Right arrow Cohort studies
Right arrow Risk factors in epidemiology
NEUROLOGY 2007;68:1902-1908
© 2007 American Academy of Neurology

Inflammatory markers and the risk of Alzheimer disease

The Framingham Study

Z. S. Tan, MD, MPH, A. S. Beiser, PhD, R. S. Vasan, MD, R. Roubenoff, MD, MHS, C. A. Dinarello, MD, T. B. Harris, MD, MS, E. J. Benjamin, MD, ScM, R. Au, PhD, D. P. Kiel, MD, MPH, P. A. Wolf, MD and S. Seshadri, MD

From the Department of Medicine, Institute for Aging Research, Hebrew Senior Life, Beth Israel Deaconess Medical Center and Harvard Medical School (Z.S.T., D.P.K.), Department of Neurology (S.S., P.A.W., R.A.) and Department of Medicine (R.S.V., E.J.B.), Boston University School of Medicine, Department of Epidemiology and Biostatistics, Boston University School of Public Health (A.B.); Tufts University School of Medicine (R.R.), Boston, MA; National Institute of Aging (T.B.H.), Bethesda, MD; and the University of Colorado Health Sciences Center (C.A.D.), Denver, CO.

Address correspondence and reprint requests to Dr. Zaldy S. Tan, Hebrew Senior Life Department of Medicine, 1200 Centre Street, Boston, MA 02131 ztan{at}hms.harvard.edu

Objective: To examine whether serum cytokines and spontaneous production of peripheral blood mononuclear cell (PBMC) cytokines are associated with the risk of incident Alzheimer disease (AD).

Methods: We followed 691 cognitively intact community-dwelling participants (mean age 79 years, 62% women) and related PBMC cytokine production (tertiles of spontaneous production of interleukin 1 [IL-1], IL-1 receptor antagonist, and tumor necrosis factor {alpha} [TNF-{alpha}]) and serum C-reactive protein and interleukin 6 (IL-6) to the risk of incident AD.

Results: Adjusting for clinical covariates, individuals in the top two tertiles (T2 and T3) of PBMC production of IL-1 or the top tertile (T3) of PBMC production of TNF-{alpha} were at increased risk of developing AD (multivariable-adjusted hazard ratio [HR] for IL-1 T2 = 2.84, 95% CI 1.09 to 7.43; p = 0.03 and T3 = 2.61, 95% CI 0.96 to 7.07; p = 0.06; for TNF-{alpha}, adjusted HR for T2 = 1.30, 95% CI 0.53 to 3.17; p = 0.57 and T3 = 2.59, 95% CI 1.09 to 6.12; p = 0.031]) compared with those in the lowest tertile (T1).

Interpretation: Higher spontaneous production of interleukin 1 or tumor necrosis factor {alpha} by peripheral blood mononuclear cells may be a marker of future risk of Alzheimer disease (AD) in older individuals. These data strengthen the evidence for a pathophysiologic role of inflammation in the development of clinical AD.


Supported by grants from the National Institute of Neurological Disorders and Stroke (5R01-NS17950), the National Institute of Aging (5R01-AG08122 and 5R01-AG16495), the Boston University Alzheimer's Disease Center (P30 AG13846), and the National Heart, Lung and Blood Institute's Framingham Heart Study (NIH/NHLBI Contract no. N01-HC-25195).

Disclosure: The authors report no conflicts of interest.

Received August 10, 2006. Accepted in final form February 1, 2007.




This article has been cited by other articles:


Home page
NeurologyHome page
E. L. Tobinick, D. L. Menkes, and Z. S. Tan
INFLAMMATORY MARKERS AND THE RISK OF ALZHEIMER DISEASE: THE FRAMINGHAM STUDY
Neurology, April 1, 2008; 70(14): 1222 - 1223.
[Full Text] [PDF]


Home page
StrokeHome page
P. B. Gorelick and J. V. Bowler
Advances in Vascular Cognitive Impairment 2007
Stroke, February 1, 2008; 39(2): 279 - 282.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Inflammatory markers and the risk of Alzheimer disease: The Framingham Study
Edward L. Tobinick
Neurology Online, 20 Aug 2007 [Full text]
Inflammatory markers and the risk of Alzheimer disease: The Framingham Study
Daniel L. Menkes, et al.
Neurology Online, 20 Aug 2007 [Full text]
Reply from the authors
Zaldy S. Tan, M.D., M.P.H.
Neurology Online, 20 Aug 2007 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.